301096 Hangzhou Bio-Sincerity Pharma-Tech
- 41.17
- +0.13+0.32%
Hangzhou Bio-Sincerity Pharma-Tech News
Baicheng Pharmaceutical: Announcement on the Company and its wholly-owned subsidiaries applying for comprehensive credit lines from banks and providing guarantees for wholly-owned subsidiaries
Baicheng Pharmaceutical: Announcement on changing the company\'s registered capital and amending the company\'s articles of association
Baicheng Pharmaceutical: Notice on Convening the First Extraordinary General Meeting of Shareholders in 2024
Hangzhou Bio-Sincerity Pharma-Tech: Summary table of non-operating fund use and other related fund transactions for the first half of 2024.
Hangzhou Bio-Sincerity Pharma-Tech: Announcement Regarding the Technology Transfer of Type 2 Improved New Drug 2022HY052
Hangzhou Bio-Sincerity Pharma-Tech: Announcement on BIOS2220 receiving a clinical trial approval notice
Hangzhou Bio-Sincerity Pharma-Tech: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Hangzhou Bio-Sincerity Pharma-Tech: Legal Opinion of Beijing Hairun Tianrui Law Firm on the 2023 Annual General Meeting of Shareholders of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd.
Hangzhou Bio-Sincerity Pharma-Tech: Announcement on BIOS2207 Obtaining Clinical Trial Approval Notice
Baicheng Pharmaceutical: Cumulative Voting System Implementation Rules
Baicheng Pharmaceutical: Summary table on the use of non-operating capital and other related capital transactions in 2023
Baicheng Pharmaceutical: Notice on amending the “Articles of Association” and registering industrial and commercial changes
Baicheng Pharmaceutical: Notice on the 2023 Annual General Meeting of Shareholders
Baicheng Pharmaceutical: Announcement on the Use of Some Idle Funds Raised and Own Funds for Cash Management
Baicheng Pharmaceutical: 2023 Internal Control Evaluation Report
Baicheng Pharmaceutical: Notice on requesting the shareholders' meeting to authorize the board of directors to fully handle matters relating to issuing shares to specific targets through simple procedures
Baicheng Pharmaceutical: Announcement on Accruing Credit Impairment Losses and Asset Impairment Losses
Baicheng Pharmaceutical: Announcement on 2023HY252 Obtaining Clinical Trial Approval Notice
Baicheng Pharmaceutical: Announcement on 2022 HY052 Obtaining a Clinical Trial Approval Notice
Baicheng Pharmaceutical: Announcement on Innovative Drug BIOS-0618 Tablets Obtaining Phase I Clinical Research Report
Analysis
Price Target
No Data
No Data